Metsera (NASDAQ:MTSR) Shares Gap Up on Analyst Upgrade

Metsera, Inc. (NASDAQ:MTSR) gapped up before the market opened on Tuesday after Guggenheim raised their price target on the stock from $56.00 to $62.00. The stock had previously closed at $30.39, but opened at $32.35. Guggenheim currently has a buy rating on the stock. Metsera shares last traded at $37.42, with a volume of 959,269 shares changing hands.

Several other equities analysts have also weighed in on MTSR. Cantor Fitzgerald started coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating for the company. Evercore ISI initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating for the company. Finally, Bank of America began coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price on the stock.

Institutional Trading of Metsera

A number of hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in Metsera in the first quarter valued at about $76,000. New York State Common Retirement Fund bought a new stake in Metsera in the first quarter worth $131,000. Corebridge Financial Inc. acquired a new position in Metsera during the first quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Metsera in the 1st quarter valued at approximately $248,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Metsera in the first quarter worth $254,000.

Metsera Trading Up 19.9%

The stock’s fifty day moving average price is $23.12.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.